Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

November/December 2015

Feature

Perspectives
12/14/2015
William Malatestinic, PharmD, MBA
David Amato, MD
Steven R. Feldman, MD, PhD
Abstract: Psoriasis is a common and significant illness characterized by systemic inflammation. In its mildest form, psoriasis can often be managed with relatively low-cost topical therapies; but for...
Abstract: Psoriasis is a common and significant illness characterized by systemic inflammation. In its mildest form, psoriasis can often be managed with relatively low-cost topical therapies; but for...
...
12/14/2015
Journal of Clinical Pathways
Research Reports
12/14/2015
Adam Lamble, MD
Thuan Nguyen MD, PhD
Susan Lindemulder, MD, MCR
David M. Spiro, MD, MPH
Suman Malempati, MD
Dawn Nolt, MD, MPH
Linda C. Stork, MD
Abstract:  The authors developed a novel clinical pathway in the pediatric emergency department (PED) of Doernbecher Children’s Hospital, Oregon Health & Science University, that endorses administering...
Abstract:  The authors developed a novel clinical pathway in the pediatric emergency department (PED) of Doernbecher Children’s Hospital, Oregon Health & Science University, that endorses administering...
...
12/14/2015
Journal of Clinical Pathways

Column

Counterpoint
12/14/2015
Joan S. McClure, MS
Al B. Benson III, MD, FACP, FASCO
Before the relative value of a drug can be determined, one must first consider how value is defined by the patient. Cancer care is expensive, and evaluating costs in cancer care is complex. Drug costs are only part...
Before the relative value of a drug can be determined, one must first consider how value is defined by the patient. Cancer care is expensive, and evaluating costs in cancer care is complex. Drug costs are only part...
Before...
12/14/2015
Journal of Clinical Pathways
Viewpoint
12/14/2015
Roger Longman, MA
Transparent comparative evaluations are necessary for determining the relative value of drugs. But, in part because of the resistance of drug companies and payers, stakeholders are finding other tools to help...
Transparent comparative evaluations are necessary for determining the relative value of drugs. But, in part because of the resistance of drug companies and payers, stakeholders are finding other tools to help...
...
12/14/2015
Journal of Clinical Pathways
Clinical Pathways GPS
12/14/2015
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Scott Guerin, PhD
Payers and at-risk providers are developing clinical pathways with great specificity regarding the preferred drugs that be used. Increasingly, these pathways will include biosimilar products. There are three major...
Payers and at-risk providers are developing clinical pathways with great specificity regarding the preferred drugs that be used. Increasingly, these pathways will include biosimilar products. There are three major...
Payers...
12/14/2015
Journal of Clinical Pathways

Insights

Interview
12/14/2015
More and more, various health care institutions around the country are implementing clinical pathways in an effort to improve outcomes and control costs. A 2003 study reported that more than 80% of hospitals had implemented clinical...
More and more, various health care institutions around the country are implementing clinical pathways in an effort to improve outcomes and control costs. A 2003 study reported that more than 80% of hospitals had implemented clinical...
More and more, various...
12/14/2015
Journal of Clinical Pathways
Interview
12/14/2015
Many institutions and health care professionals have been aware of the staggering rise of health care costs. An IMS Health report published in May of 2015 confirmed that drug sales in the United States surpassed $100...
Many institutions and health care professionals have been aware of the staggering rise of health care costs. An IMS Health report published in May of 2015 confirmed that drug sales in the United States surpassed $100...
Many...
12/14/2015
Journal of Clinical Pathways

Department

Research in Review
12/14/2015
JCP Editors
Routine imaging for diffuse large B-cell lymphoma (DLBCL) in patients after first complete remission does not translate into better survival, suggests a study in the online Journal of Clinical Oncology. Considering...
Routine imaging for diffuse large B-cell lymphoma (DLBCL) in patients after first complete remission does not translate into better survival, suggests a study in the online Journal of Clinical Oncology. Considering...
...
12/14/2015
Journal of Clinical Pathways
Research in Review
12/11/2015
JCP Editors
Two new studies suggest a role for blood tests, or liquid biopsies, in guiding a patient’s cancer treatment. The research, which involved patients with breast and prostate cancers, scanned blood for traces of...
Two new studies suggest a role for blood tests, or liquid biopsies, in guiding a patient’s cancer treatment. The research, which involved patients with breast and prostate cancers, scanned blood for traces of...
Two...
12/11/2015
Journal of Clinical Pathways
Research in Review
12/11/2015
JCP Editors
The American Society of Clinical Oncology (ASCO) issued updated antiemetic guidelines recommending that patients who receive highly emetogenic chemotherapy regimens be offered a 3-drug combination of a neurokinin 1...
The American Society of Clinical Oncology (ASCO) issued updated antiemetic guidelines recommending that patients who receive highly emetogenic chemotherapy regimens be offered a 3-drug combination of a neurokinin 1...
The...
12/11/2015
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement